BostonGene, a leader in AI-driven molecular and immune profiling solutions, has announced that 10 of its abstracts have been selected for poster presentations, and two will be featured for online publication at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 7-10, 2024, in San Diego, California. BostonGene will also be exhibiting at booth #1955.
“We are thrilled to present our findings at ASH, showcasing the transformative potential of integrating molecular and immune profiling with advanced analytics. This approach is crucial for advancing precision medicine and improving outcomes for cancer patients,” said Nathan Fowler, MD, Chief Medical Officer at BostonGene.
The selected presentations include:
- Abstract 1593: A machine learning-based classifier for diagnosing peripheral T-cell lymphoma (PTCL-NOS), improving subtype classification in over 400 cases, conducted in collaboration with Weill Cornell Medicine.
- Abstract 3610: A novel liquid biopsy approach using plasma cell-free RNA to monitor chronic lymphocytic leukemia (CLL) dynamics and minimal residual disease, developed with Massachusetts General Hospital and Harvard Medical School.
- Abstract 2981: A gene expression-based classifier for reclassifying high-grade B-cell lymphomas, which could enhance treatment strategies, developed with the Sylvester Comprehensive Cancer Center at the University of Miami.
- Abstract 3038: Acalabrutinib and rituximab as effective first-line treatment for older patients with mantle cell lymphoma, showing a 94% overall response rate, conducted with the MD Anderson Cancer Center.
- Abstract 2982: The use of molecular immune signatures to guide frontline treatment in advanced-stage follicular lymphoma, developed with the MD Anderson Cancer Center.
- Abstract 2958: Circulating tumor DNA as a predictor for outcomes in follicular lymphoma, offering a minimally invasive monitoring tool, conducted in collaboration with the National Institutes of Health and other research institutions.
- Abstract 4341: A comprehensive analysis of malignant B-cell receptors in B-cell lymphoma, revealing diagnostic biomarkers, conducted with BostonGene.
- Abstract 4377: The impact of radiation therapy on monocyte activation in large B-cell lymphoma patients undergoing CAR T-cell therapy, conducted in collaboration with the MD Anderson Cancer Center.
- Abstract 4348: Genomic and spatial proteomic analysis of the microenvironment in African American diffuse large B-cell lymphoma (DLBCL) patients, with findings suggesting disparities in survival outcomes, conducted with the Winship Cancer Institute of Emory University.
- Abstract 4364: The clinical utility of whole exome sequencing and RNA-seq for lymphoma patients, demonstrating rapid, clinically relevant findings, conducted in collaboration with the MD Anderson Cancer Center.
Additionally, two abstracts will be presented online only:
- Tumor Genomics and Microenvironment Characterization of DLBCL in Asian and Pacific Islander Patients: This study highlights the need for more diverse patient populations to understand DLBCL’s pathobiology.
- Comprehensive Molecular Characterization of Post-Transplant Lymphoproliferative Disorder (PTLD): This analysis sheds light on distinct immune signatures and molecular features associated with EBV-positive PTLD patients.
These abstracts have been published online in the November supplemental issue of Blood.
About BostonGene Corporation
BostonGene is a biotechnology company specializing in computational biology and precision medicine. Founded in 2015, the company utilizes its AI-powered multiomics platform to decode cancer patients’ molecular profiles, helping identify disease drivers, drug targets, and optimal treatments. With a CLIA-certified, CAP-accredited laboratory and advanced bioanalytics, BostonGene is advancing oncology research and improving patient care.
